| ASO | Antisense oligonucleotide |
| CAF | Cancer-associated fibroblast |
| CNS | Central nervous system |
| CRC | Colorectal cancer |
| ctDNA | Circulating tumor DNA |
| ECM | Extracellular matrix |
| EGFR | Epidermal growth factor receptor |
| EMT | Epithelial-to-mesenchymal transition |
| FDA | U.S. Food and Drug Administration |
| FTI | Farnesyltransferase inhibitor |
| GAP | GTPase-activating protein |
| GDP | Guanosine diphosphate |
| GEF | Guanine nucleotide exchange factor |
| GTP | Guanosine triphosphate |
| HR | Hazard ratio |
| MAPK | Mitogen-activated protein kinase |
| MEK | Mitogen-activated protein kinase kinase |
| mCRC | Metastatic colorectal cancer |
| MRD | Minimal residual disease |
| NSCLC | Non-small-cell lung cancer |
| ORR | Objective response rate |
| OS | Overall survival |
| PDAC | Pancreatic ductal adenocarcinoma |
| PFS | Progression-free survival |
| PI3K | Phosphoinositide 3-kinase |
| PROTAC | Proteolysis-targeting chimera |
| RAF | Rapidly accelerated fibrosarcoma kinase |
| RAS(ON) | Active-state RAS |
| RTK | Receptor tyrosine kinase |
| SHP2 | Src homology region 2-containing protein tyrosine phosphatase 2 |
| S-IIP | Switch-II pocket |
| siRNA | Small interfering RNA |
| SOS1 | Son of sevenless homolog 1 |
| TME | Tumor microenvironment |